tetano
Editor, Senior Moderator
Access Microbiol
. 2021 Aug 26;3(8):000257.
doi: 10.1099/acmi.0.000257. eCollection 2021.
Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
Inna Sekirov[SUP] 1 2 [/SUP], Martin Petric[SUP] 1 2 [/SUP], Erin Carruthers[SUP] 1 [/SUP], David Lawrence[SUP] 1 [/SUP], Tamara Pidduck[SUP] 1 [/SUP], Jesse Kustra[SUP] 1 [/SUP], Jonathan Laley[SUP] 1 [/SUP], Min-Kuang Lee[SUP] 1 [/SUP], Navdeep Chahil[SUP] 1 [/SUP], Annie Mak[SUP] 1 [/SUP], Paul N Levett[SUP] 1 2 [/SUP], Emelissa Mendoza[SUP] 3 [/SUP], Heidi Wood[SUP] 3 [/SUP], Mike Drebot[SUP] 3 [/SUP], Mel Krajden[SUP] 1 2 [/SUP], Muhammad Morshed[SUP] 1 2 [/SUP]
Affiliations
Abstract
We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies' neutralizing capacity outside CL-3 laboratory containment.
Keywords: COVID-19; PRNT; SARS CoV-2; enzyme immunoassay; microneutralization; neutralization; serology.
. 2021 Aug 26;3(8):000257.
doi: 10.1099/acmi.0.000257. eCollection 2021.
Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
Inna Sekirov[SUP] 1 2 [/SUP], Martin Petric[SUP] 1 2 [/SUP], Erin Carruthers[SUP] 1 [/SUP], David Lawrence[SUP] 1 [/SUP], Tamara Pidduck[SUP] 1 [/SUP], Jesse Kustra[SUP] 1 [/SUP], Jonathan Laley[SUP] 1 [/SUP], Min-Kuang Lee[SUP] 1 [/SUP], Navdeep Chahil[SUP] 1 [/SUP], Annie Mak[SUP] 1 [/SUP], Paul N Levett[SUP] 1 2 [/SUP], Emelissa Mendoza[SUP] 3 [/SUP], Heidi Wood[SUP] 3 [/SUP], Mike Drebot[SUP] 3 [/SUP], Mel Krajden[SUP] 1 2 [/SUP], Muhammad Morshed[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34888485
- PMCID: PMC8650845
- DOI: 10.1099/acmi.0.000257
Abstract
We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies' neutralizing capacity outside CL-3 laboratory containment.
Keywords: COVID-19; PRNT; SARS CoV-2; enzyme immunoassay; microneutralization; neutralization; serology.